Dren Bio, Inc.
Biotechnology ResearchCalifornia, United States51-200 Employees
Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Strategic Collaborations Dren Bio, Inc. has established a strategic collaboration with Novartis for developing novel Targeted Myeloid engagers for cancer. This partnership presents a sales opportunity to leverage the credibility of working with a major player in the pharmaceutical industry.
Revenue Growth Potential Recent financing of $150M in equity investment, with an upfront payment of $150 million, including $25 million from Novartis, indicates strong financial backing. This infusion of funds positions Dren Bio for potential revenue growth and opens doors for increased sales activities.
Key Personnel Appointment Amit Mehta was appointed as the Chief Operating Officer and Chief Business Officer at Dren Bio, Inc. His role in expanding the leadership team signifies a focus on operational and business aspects, indicating potential sales strategies led by experienced personnel.
Focus on Bispecific Antibodies Dren Bio, Inc. is actively developing bispecific antibodies for cancer, evident from a $3 billion agreement with Novartis Pharma. This specialization in cutting-edge treatments presents an attractive sales opportunity within the oncology market.
C-Level Movements Dr. Will, former Chief Medical Officer at Dren Bio, Inc., has joined Autolus. This transition highlights potential sales outreach to the network and connections of Dr. Will, leveraging relationships for business development opportunities.
Dren Bio, Inc. uses 8 technology products and services including cdnjs, Font Awesome, Ionicons, and more. Explore Dren Bio, Inc.'s tech stack below.
Dren Bio, Inc. Email Formats | Percentage |
FLast@drenbio.com | 50% |
FLast@drenbio.com | 50% |
Biotechnology ResearchCalifornia, United States51-200 Employees
Dren Bio is a Foster City, CA based biotechnology company, developing power protein-based technologies to deplete pathogenic cells and agents in numerous diseases.
Dren Bio, Inc. has raised a total of $25M of funding over 5 rounds. Their latest funding round was raised on Jul 24, 2024 in the amount of $25M.
Dren Bio, Inc.'s revenue is in the range of $10M
Dren Bio, Inc. has raised a total of $25M of funding over 5 rounds. Their latest funding round was raised on Jul 24, 2024 in the amount of $25M.
Dren Bio, Inc.'s revenue is in the range of $10M